- Home
- NAII vs ESLA Comparison
NAII vs ESLA Comparison
Compare NAII & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAII
- ESLA
- Stock Information
- Founded
- NAII 1980
- ESLA 2021
- Country
- NAII United States
- ESLA United States
- Employees
- NAII N/A
- ESLA N/A
- Industry
- NAII Medicinal Chemicals and Botanical Products
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NAII Health Care
- ESLA Health Care
- Exchange
- NAII Nasdaq
- ESLA Nasdaq
- Market Cap
- NAII 28.0M
- ESLA 41.6M
- IPO Year
- NAII 1987
- ESLA N/A
- Fundamental
- Price
- NAII $4.42
- ESLA $0.82
- Analyst Decision
- NAII
- ESLA
- Analyst Count
- NAII 0
- ESLA 0
- Target Price
- NAII N/A
- ESLA N/A
- AVG Volume (30 Days)
- NAII 18.2K
- ESLA 370.5K
- Earning Date
- NAII 11-07-2024
- ESLA 11-01-2024
- Dividend Yield
- NAII N/A
- ESLA N/A
- EPS Growth
- NAII N/A
- ESLA N/A
- EPS
- NAII N/A
- ESLA N/A
- Revenue
- NAII $113,796,000.00
- ESLA N/A
- Revenue This Year
- NAII N/A
- ESLA N/A
- Revenue Next Year
- NAII N/A
- ESLA N/A
- P/E Ratio
- NAII N/A
- ESLA N/A
- Revenue Growth
- NAII N/A
- ESLA N/A
- 52 Week Low
- NAII $4.13
- ESLA $0.77
- 52 Week High
- NAII $7.37
- ESLA $3.23
- Technical
- Relative Strength Index (RSI)
- NAII 35.54
- ESLA 39.62
- Support Level
- NAII $4.22
- ESLA $0.87
- Resistance Level
- NAII $4.62
- ESLA $1.24
- Average True Range (ATR)
- NAII 0.30
- ESLA 0.12
- MACD
- NAII -0.02
- ESLA -0.01
- Stochastic Oscillator
- NAII 30.23
- ESLA 12.57
About NAII Natural Alternatives International Inc.
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.